Predictive value of pre-transplant platelet to lymphocyte ratio for hepatocellular carcinoma recurrence after liver transplantation

World Journal of Surgical Oncology

Volumn 13, Issue 1, 2015, Pages

  Xia, Weiliang ^a   Ke, Qinghong ^a   Wang, Ye ^a   Wang, Weilin ^a   Zhang, Min ^a   Shen, Yan ^a   Wu, Jian ^a   Xu, Xiao ^a   Zheng, Shusen ^a  

^a ZHEJIANG UNIVERSITY   (China)

Author keywords

Hepatocellular carcinoma; Liver transplantation; Platelet to lymphocyte ratio

Indexed keywords

ADULT; AGED; ARTICLE; CANCER RECURRENCE; CANCER STAGING; CLINICAL STUDY; DISEASE FREE SURVIVAL; FEMALE; FOLLOW UP; HUMAN; LIVER CELL CARCINOMA; LIVER TRANSPLANTATION; LYMPHOCYTE COUNT; MAJOR CLINICAL STUDY; MALE; MULTIPLE CANCER; PLATELET LYMPHOCYTE RATIO; PREDICTIVE VALUE; RECEIVER OPERATING CHARACTERISTIC; RETROSPECTIVE STUDY; SENSITIVITY AND SPECIFICITY; SURVIVAL RATE; THROMBOCYTE COUNT; TUMOR INVASION; TUMOR VOLUME; CARCINOMA, HEPATOCELLULAR; LIVER NEOPLASMS; LYMPHOCYTE; MIDDLE AGED; MORTALITY; PATHOLOGY; PATIENT SELECTION; PROGNOSIS; RISK FACTOR; THROMBOCYTE; TUMOR RECURRENCE;

BLOOD PLATELETS; CARCINOMA, HEPATOCELLULAR; FEMALE; FOLLOW-UP STUDIES; HUMANS; LIVER NEOPLASMS; LIVER TRANSPLANTATION; LYMPHOCYTES; MALE; MIDDLE AGED; NEOPLASM INVASIVENESS; NEOPLASM RECURRENCE, LOCAL; NEOPLASM STAGING; PATIENT SELECTION; PROGNOSIS; RETROSPECTIVE STUDIES; RISK FACTORS; ROC CURVE; SURVIVAL RATE;

EID: 84924178288     PISSN: None     EISSN: 14777819     Source Type: Journal    
DOI: 10.1186/s12957-015-0472-2     Document Type: Article

References (31)

1. El-Serag HB. Hepatocellular carcinoma. N Engl J Med. 2011;365:1118-27.
2. Mazzaferro V, Regalia E, Doci R, Andreola S, Pulvirenti A, Bozzetti F, et al. Liver transplantation for the treatment of small hepatocellular carcinomas in patients with cirrhosis. N Engl J Med. 1996;334:693-9.
3. Mazzaferro V, Bhoori S, Sposito C, Bongini M, Langer M, Miceli R, et al. Milan criteria in liver transplantation for hepatocellular carcinoma: an evidence-based analysis of 15years of experience. Liver Transpl. 2011;17 Suppl 2:S44-57.
4. Prasad KR, Young RS, Burra P, Zheng SS, Mazzaferro V, Moon DB, et al. Summary of candidate selection and expanded criteria for liver transplantation for hepatocellular carcinoma: a review and consensus statement. Liver Transpl. 2011;17 Suppl 2:S81-89.
5. Yao FY, Ferrell L, Bass NM, Watson JJ, Bacchetti P, Venook A, et al. Liver transplantation for hepatocellular carcinoma: expansion of the tumor size limits does not adversely impact survival. Hepatology. 2001;33:1394-403.
6. Zheng SS, Xu X, Wu J, Chen J, Wang WL, Zhang M, et al. Liver transplantation for hepatocellular carcinoma: Hangzhou experiences. Transplantation. 2008;85:1726-32.
7. Freeman RB, Mithoefer A, Ruthazer R, Nguyen K, Schore A, Harper A, et al. Optimizing staging for hepatocellular carcinoma before liver transplantation: a retrospective analysis of the UNOS/OPTN database. Liver Transpl. 2006;12:1504-11.
8. Ciccarelli O, Lai Q, Goffette P, Finet P, De Reyck C, Roggen F, et al. Liver transplantation for hepatocellular cancer: UCL experience in 137 adult cirrhotic patients. Alpha-foetoprotein level and locoregional treatment as refined selection criteria. Transpl Int. 2012;25:867-75.
9. Li WX, Li Z, Gao PJ, Gao J, Zhu JY. Histological differentiation predicts post-liver transplantation survival time. Clin Res Hepatol Gastroenterol. 2014;38:201-8.
10. Toso C, Asthana S, Bigam DL, Shapiro AM, Kneteman NM. Reassessing selection criteria prior to liver transplantation for hepatocellular carcinoma utilizing the Scientific Registry of Transplant Recipients database. Hepatology. 2009;49:832-8.
11. Coussens LM, Werb Z. Inflammation and cancer. Nature. 2002;420:860-7.
12. Mantovani A, Allavena P, Sica A, Balkwill F. Cancer-related inflammation. Nature. 2008;454:436-44.
13. Neofytou K, Smyth EC, Giakoustidis A, Khan AZ, Cunningham D, Mudan S. Elevated platelet to lymphocyte ratio predicts poor prognosis after hepatectomy for liver-only colorectal metastases, and it is superior to neutrophil to lymphocyte ratio as an adverse prognostic factor. Med Oncol. 2014;31:239.
14. Krenn-Pilko S, Langsenlehner U, Thurner EM, Stojakovic T, Pichler M, Gerger A, et al. The elevated preoperative platelet-to-lymphocyte ratio predicts poor prognosis in breast cancer patients. Br J Cancer. 2014;110:2524-30.
15. Kilincalp S, Coban S, Akinci H, Hamamc M, Karaahmet F, Coskun Y, Ustun Y, Simsek Z, Erarslan E, Yuksel I: Neutrophil/lymphocyte ratio, platelet/lymphocyte ratio, and mean platelet volume as potential biomarkers for early detection and monitoring of colorectal adenocarcinoma. Eur J Cancer Prev. 2014 Oct 9. [Epub ahead of print].
16. Lai Q, Castro Santa E, Rico Juri JM, Pinheiro RS, Lerut J. Neutrophil and platelet-to-lymphocyte ratio as new predictors of dropout and recurrence after liver transplantation for hepatocellular cancer. Transpl Int. 2014;27:32-41.
17. Pinato DJ, Stebbing J, Ishizuka M, Khan SA, Wasan HS, North BV, et al. A novel and validated prognostic index in hepatocellular carcinoma: the inflammation based index (IBI). J Hepatol. 2012;57:1013-20.
18. Kinoshita A, Onoda H, Imai N, Iwaku A, Oishi M, Fushiya N, et al. Comparison of the prognostic value of inflammation-based prognostic scores in patients with hepatocellular carcinoma. Br J Cancer. 2012;107:988-93.
19. Zhou X, Du Y, Huang Z, Xu J, Qiu T, Wang J, et al. Prognostic value of PLR in various cancers: a meta-analysis. PLoS One. 2014;9:e101119.
20. Hemming AW, Cattral MS, Reed AI, Van Der Werf WJ, Greig PD, Howard RJ. Liver transplantation for hepatocellular carcinoma. Ann Surg. 2001;233:652-9.
21. Jonas S, Bechstein WO, Steinmuller T, Herrmann M, Radke C, Berg T, et al. Vascular invasion and histopathologic grading determine outcome after liver transplantation for hepatocellular carcinoma in cirrhosis. Hepatology. 2001;33:1080-6.
22. Schwartz ME, D'Amico F, Vitale A, Emre S, Cillo U. Liver transplantation for hepatocellular carcinoma: Are the Milan criteria still valid? Eur J Surg Oncol. 2008;34:256-62.
23. Walsh SR, Cook EJ, Goulder F, Justin TA, Keeling NJ. Neutrophil-lymphocyte ratio as a prognostic factor in colorectal cancer. J Surg Oncol. 2005;91:181-4.
24. Dominguez I, Fernandez-del CC. Preoperative platelet-lymphocyte ratio in resected pancreatic ductal carcinoma: is it meaningful? Am J Surg. 2012;203:412.
25. Wu XS, Shi LB, Li ML, Ding Q, Weng H, Wu WG, et al. Evaluation of two inflammation-based prognostic scores in patients with resectable gallbladder carcinoma. Ann Surg Oncol. 2014;21:449-57.
26. Kwon HC, Kim SH, Oh SY, Lee S, Lee JH, Choi HJ, et al. Clinical significance of preoperative neutrophil-lymphocyte versus platelet-lymphocyte ratio in patients with operable colorectal cancer. Biomarkers. 2012;17:216-22.
27. Wang D, Wu M, Feng FZ, Huang HF, Yang JX, Shen K, et al. Pretreatment neutrophil-to-lymphocyte and platelet-to-lymphocyte ratios do not predict survival in patients with cervical cancer treated with neoadjuvant chemotherapy and radical hysterectomy. Chin Med J (Engl). 2013;126:1464-8.
28. Azab B, Shah N, Radbel J, Tan P, Bhatt V, Vonfrolio S, et al. Pretreatment neutrophil/lymphocyte ratio is superior to platelet/lymphocyte ratio as a predictor of long-term mortality in breast cancer patients. Med Oncol. 2013;30:432.
29. Bambace NM, Holmes CE. The platelet contribution to cancer progression. J Thromb Haemost. 2011;9:237-49.
30. Dunn GP, Old LJ, Schreiber RD. The immunobiology of cancer immunosurveillance and immunoediting. Immunity. 2004;21:137-48.
31. Motomura T, Shirabe K, Mano Y, Muto J, Toshima T, Umemoto Y, et al. Neutrophil-lymphocyte ratio reflects hepatocellular carcinoma recurrence after liver transplantation via inflammatory microenvironment. J Hepatol. 2013;58:58-64.